X4 Pharmaceuticals, Inc Quarterly Operating Income (Loss) in USD from Q1 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
X4 Pharmaceuticals, Inc quarterly/annual Operating Income (Loss) history and growth rate from Q1 2017 to Q3 2024.
  • X4 Pharmaceuticals, Inc Operating Income (Loss) for the quarter ending September 30, 2024 was -$34.5M, a 26.8% decline year-over-year.
  • X4 Pharmaceuticals, Inc Operating Income (Loss) for the twelve months ending September 30, 2024 was -$25.9M, a 76% increase year-over-year.
  • X4 Pharmaceuticals, Inc annual Operating Income (Loss) for 2023 was -$108M, a 22.8% decline from 2022.
  • X4 Pharmaceuticals, Inc annual Operating Income (Loss) for 2022 was -$87.6M, a 2.89% decline from 2021.
  • X4 Pharmaceuticals, Inc annual Operating Income (Loss) for 2021 was -$85.1M, a 42.1% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$25.9M -$34.5M -$7.29M -26.8% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$18.6M $71.1M +$96.9M Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$116M -$37.3M -$7.99M -27.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 -$108M -$25.2M +$378K +1.48% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 -$108M -$27.2M -$7.06M -35% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$101M -$25.8M -$5.24M -25.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$95.6M -$29.3M -$8.04M -37.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$87.6M -$25.6M +$3.48M +12% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 -$91M -$20.2M -$1.04M -5.41% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$90M -$20.6M -$1.57M -8.28% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$88.4M -$21.3M -$3.33M -18.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$85.1M -$29.1M -$11.4M -64.6% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-21
Q3 2021 -$73.7M -$19.1M -$2.14M -12.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$71.6M -$19M -$4.34M -29.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$67.2M -$17.9M -$7.36M -69.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$59.9M -$17.7M -$6.78M -62.3% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-21
Q3 2020 -$53.1M -$17M -$4K -0.02% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$53.1M -$14.7M -$1.24M -9.27% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 -$51.8M -$10.6M -$143K -1.37% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$51.7M -$10.9M -$2.82M -35% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-17
Q3 2019 -$48.9M -$17M -$8.43M -98.7% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$40.5M -$13.4M -$7.04M -110% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-04
Q1 2019 -$33.4M -$10.4M -$4.33M -70.8% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$29.1M -$8.05M -$10.3M -453% Oct 1, 2018 Dec 31, 2018 10-K 2021-03-19
Q3 2018 -$18.8M -$8.55M +$4.51M +34.6% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$23.3M -$6.38M -$732K -13% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 -$22.5M -$6.11M -$283K -4.86% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
Q4 2017 -$22.2M $2.28M Oct 1, 2017 Dec 31, 2017 10-K 2020-03-12
Q3 2017 -$13.1M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 -$5.64M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-13
Q1 2017 -$5.83M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.